Sofie Wilgenhof

5.0k citations
86 papers · 2.7k · 1 hit paper · h-index 25

Impact in

  • Immunology top 2%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction
  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research

Papers in

    • Cancer Immunotherapy and Biomarkers 39
    • CAR-T cell therapy research 37
    • Cutaneous Melanoma Detection and Management 15
    • Melanoma and MAPK Pathways 22
    • RNA Interference and Gene Delivery 9
    • vaccines and immunoinformatics approaches 7

Sofie Wilgenhof

82 papers receiving 2.6k citations

Sofie Wilgenhof's Hit Papers

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors 2021 · 257 citations
2570+1+3Years since publication50100150200250

Peers

Sofie Wilgenhof
Comparison fields: 5 of 100
  • Immunology 1.4k
  • Oncology 1.8k
  • Molecular Biology 1.1k
  • Cancer Research 211
  • Pulmonary and Respiratory Medicine 391
Replace Pia Kvistborg with:
Pia Kvistborg Netherlands
Cara Haymaker United States
Marka R. Crittenden United States
William L. Redmond United States
Natalia Aptsiauri Spain
Cristina Puig-Saus United States
Christoph Höeller Austria
Colm R. Duffy United States
Hung T. Khong United States
Jasreet Hundal United States
Sofie Wilgenhof relative to Pia Kvistborg Netherlands Pia Kvistborg's profile →
Citations per field
00.5×1.6×
Pia Kvistborg · 1×
Citations per year

Countries citing papers authored by Sofie Wilgenhof

Since Specialization
Citations

This map shows the geographic impact of Sofie Wilgenhof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofie Wilgenhof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofie Wilgenhof more than expected).

Fields of papers citing papers by Sofie Wilgenhof

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofie Wilgenhof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofie Wilgenhof. The network helps show where Sofie Wilgenhof may publish in the future.

Co-authors

The 25 scholars most cited alongside Sofie Wilgenhof, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sofie Wilgenhof Line = papers co-authored together Sofie Wilgenhof links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 86 papers — load more, or switch the sort, to bring in the rest.

#Work
1 2018281
2
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Hit paper breakdown →
2021257
3 2016240
4 2013170
5 2011142
6 2011118
7 2020118
8 2016116
9 201291
10 201280
11 201475
12 201368
13
Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.
201266
14 201364
15 201463
16 201153
17 201245
18 201242
19 201433
20 201533

About Sofie Wilgenhof

Sofie Wilgenhof is a scholar working on Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 86 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (39 papers), CAR-T cell therapy research (37 papers), Immunotherapy and Immune Responses (36 papers), Melanoma and MAPK Pathways (22 papers), Cutaneous Melanoma Detection and Management (15 papers), RNA Interference and Gene Delivery (9 papers), Renal cell carcinoma treatment (7 papers) and vaccines and immunoinformatics approaches (7 papers). The work is most often cited by research in Immunology (1.4k citations), Oncology (1.8k citations), Molecular Biology (1.1k citations), Cancer Research (211 citations) and Pulmonary and Respiratory Medicine (391 citations). Sofie Wilgenhof has collaborated with scholars based in Belgium, Netherlands and United States. Frequent co-authors include Bart Neyns, Kris Thielemans, Jurgen Corthals, John B.A.G. Haanen, Carlo Heirman, Maartje W. Rohaan, Aude Bonehill, An M. T. Van Nuffel, Daphné Benteyn and Nicolas van Baren. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Melanoma Research, Cancer Immunology Immunotherapy and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact